For the first quarter of FY-22 listed steel stocks have generated profits that are already three-fourth that of the full year ending FY-21. The sector has thus stood out for its June quarter earnings, the 2nd wave of Covid lockdown and drop in consumption notwithstanding. Higher prices and export opportunities buttressed earnings despite a drop in domestic sales.
Federal Bank is charting a different course with a significant thrust on technology, digital adoption and diversification into new retail segments in the last five years.
Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?
A company’s Annual Report is a statutory document that contains material facts and information about the company. This makes it among the most reliable sources for information on a company. In this article, we will try to give examples of where in an annual report you can find information that is useful for your understanding of business and financials. This is an illustrative article and not an exhaustive one.
Mobility powered by electricity is fast becoming a reality. And one space that is expected to see accelerated adoption of electric vehicles is the basic commuter space, made up of 2- wheelers, particularly scooters. Scooters are mostly used for short commutes, their electric versions have a more affordable purchase price after FAME II (Faster Adoption and Manufacturing of EV) subsidy and they have lower running costs than petrol scooters. With almost 40 lakh scooters sold in India in a year, annual sales of 40,000 units for high-speed EV scooters look small. There is scope for faster adoption driven by basic commuting, e-commerce, and low speed mobility needs.
Last month, we reviewed a lesser-known a consolidation play in the commodity space play as a story fitting a ‘special situations’ theme. We now issue a ‘buy’ call on this stock and recommend accumulating the stock in phases, preferably adding on dips, if opportunities arise.
India Pesticides is launching an IPO totalling to Rs 800 crore – with fresh issue of shares worth Rs 100 crore and an offer for sale worth Rs 700 crore by the promoter group. At the upper end of the price band of Rs 290-296 the post-issue market cap of the stock on listing would be Rs3,400 crore and the post-issue price earnings ratio would be 25 times. The offer closes on June 25. The proceeds from fresh issues are planned to be utilised towards working capital requirement and other corporate purposes.
Have you been led to believe that multibaggers picked by popular investors are purely the result of skill, timing and foresight? Well, it’s often luck
Automotive components manufacturer Sona BLW Precision Forgings (Sona Comstar) has come out with an IPO totalling to Rs 5,550 crore – with fresh issue of
In these reviews, we pick stocks that have rallied, or where businesses are interesting or changing, or where companies may be relatively unknown and so
Even as the economy is battling with the second wave of Covid-19, supply chain appears to be smoother than when the pandemic began. After 2
The stock of Tata Steel Long Products (TSLP) offers an interesting case study on how a commodity business in an unexciting category can acquire scale,
The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research services before onboarding. History, Present business and Background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services. Terms and conditions of Research Services: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Analyst never guarantees the returns on the recommendation provided. Investor shall take note that Investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The Research Analyst shall not be responsible for any loss to the Investors. Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made there under against the Research Analyst relating to Research Analyst services. Details of its associates: No associates. Disclosures with respect to Research and Recommendations Services: The Research Analyst or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of Research Analyst services. Such conflict of interest shall be disclosed to the client as and when they arise. Research Analyst or its directors or its employee or its associates have not received any compensation from the company which is subject matter of recommendation. Research Analyst or its directors or its employee or its associates have not managed or co-managed the public offering of any company. Research Analyst or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation. The subject company was not a client of Research Analyst or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided. Research Analysts or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.
Full disclosures and disclaimers
Compliance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
Grievance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
